Linked Life Data

17057185

Source:http://linkedlifedata.com/resource/pubmed/id/17057185

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-10-23
pubmed:abstractText
Great progress has been made over the last decade in the development of targeted specific therapies for inflammatory bowel disease. Nevertheless, accumulating experience with these modalities and results from ongoing investigations of agents currently on the market and those in development have demonstrated that efficacy may be limited to certain patient phenotypes. Recently, great interest has been applied to studies of the interplay between the adaptive and innate immune responses to achieve a better understanding of the immunopathogeneses of inflammatory bowel diseases as well as to identify targets for even more potent intervention.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0077-8923
pubmed:author
pubmed:issnType
Print
pubmed:volume
1072
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-8
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Current limitations of IBD treatment: where do we go from here?
pubmed:affiliation
Cedars-Sinai Medical Center, 8700 Beverly Blvd., Suite D4063, Los Angeles, CA 90048, USA. Stephan.Targan@cshs.org
pubmed:publicationType
Journal Article, Review